Arvinas, Inc. filings document regulatory, clinical, financial, and governance disclosures for a biotechnology company built around PROTAC targeted protein degradation. Recent Form 8-K reports cover FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, clinical data for ARV-102 in Parkinson’s disease, preclinical data for ARV-806 as a KRAS G12D degrader, and patient-reported outcomes for vepdegestrant.
The company’s filings also record quarterly and annual financial results, corporate updates, executive and board leadership changes, and proxy matters. Its definitive proxy statement addresses board elections, executive compensation, equity awards, shareholder voting items, and other governance information for Arvinas as a Nasdaq-listed operating company.
Arvinas, Inc.'s Chief Financial Officer Andrew Saik reported an automatic sale of 11,139 shares of common stock at $9.9374 per share. The shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units granted on May 9, 2025, and the transaction was not a discretionary trade. After this sale, Saik directly holds 193,128 shares of Arvinas common stock.
ARVINAS, INC. executive David K. Loomis, VP and Chief Accounting Officer, had 1,919 shares of common stock sold on May 11, 2026 at $9.9374 per share. According to the footnote, this automatic sale by the company covered tax withholding on vested RSUs and was not a discretionary trade. After this transaction, Loomis directly holds 40,193 shares of Arvinas common stock.
Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic share sale tied to tax withholding. On May 11, 2026, she sold 9,657 shares of common stock at $9.9374 per share. According to the footnote, this sale was made by the company to cover tax obligations from the vesting and settlement of RSUs granted on May 9, 2025 and "does not represent a discretionary trade." After the transaction, she directly owned 182,966 shares of Arvinas common stock.
Arvinas, Inc.’s Chief Medical Officer, Noah Berkowitz, reported a sale of 11,108 shares of common stock at an average price of $9.9374 per share on May 11, 2026. According to the filing, the sale was made automatically by the company to cover tax withholding obligations tied to the vesting and settlement of half of his RSUs granted on May 9, 2025, and is not a discretionary trade. Following this tax-related sale, Berkowitz directly holds 191,395 shares of Arvinas common stock.
ARVINAS, INC. reported that President and CEO Randy Teel had 9,657 shares of Common Stock sold on May 11, 2026 at an average price of $9.9374 per share.
According to the disclosure, this sale was made automatically by the company to cover tax withholding obligations tied to the vesting and settlement of restricted stock units granted on May 9, 2025, and is not a discretionary trade. Following the transaction, Teel directly holds 287,218 shares of Arvinas common stock.
Arvinas, Inc. reported first quarter 2026 results and highlighted a major strategic milestone: FDA approval of VEPPANU (vepdegestrant), the first-ever approved PROTAC protein degrader, for ESR1-mutated ER+/HER2- advanced or metastatic breast cancer after at least one line of endocrine therapy. VEPPANU was also added as a Category 2A treatment in the NCCN Breast Cancer Guidelines and is being outlicensed globally to Rigel Pharmaceuticals, with closing subject to customary approvals.
For the quarter ended March 31, 2026, revenue was $15.6 million compared with $188.8 million a year earlier, mainly reflecting lower Pfizer collaboration revenue. Arvinas posted a net loss of $57.6 million versus net income of $82.9 million in the prior-year quarter. GAAP R&D expenses fell to $60.3 million and GAAP G&A to $19.1 million, with non-GAAP R&D and G&A at $54.3 million and $13.0 million, respectively. Cash, cash equivalents, and marketable securities totaled $614.9 million as of March 31, 2026, which the company believes will fund operations into the second half of 2028, while it advances a broad PROTAC pipeline including ARV-102, ARV-806, ARV-393, ARV-027, and ARV-6723.
Arvinas, Inc. reported first quarter 2026 results and highlighted a major strategic milestone: FDA approval of VEPPANU (vepdegestrant), the first-ever approved PROTAC protein degrader, for ESR1-mutated ER+/HER2- advanced or metastatic breast cancer after at least one line of endocrine therapy. VEPPANU was also added as a Category 2A treatment in the NCCN Breast Cancer Guidelines and is being outlicensed globally to Rigel Pharmaceuticals, with closing subject to customary approvals.
For the quarter ended March 31, 2026, revenue was $15.6 million compared with $188.8 million a year earlier, mainly reflecting lower Pfizer collaboration revenue. Arvinas posted a net loss of $57.6 million versus net income of $82.9 million in the prior-year quarter. GAAP R&D expenses fell to $60.3 million and GAAP G&A to $19.1 million, with non-GAAP R&D and G&A at $54.3 million and $13.0 million, respectively. Cash, cash equivalents, and marketable securities totaled $614.9 million as of March 31, 2026, which the company believes will fund operations into the second half of 2028, while it advances a broad PROTAC pipeline including ARV-102, ARV-806, ARV-393, ARV-027, and ARV-6723.
Arvinas, Pfizer and Rigel have signed a major licensing deal for VEPPANU. Rigel will receive exclusive global rights to develop, manufacture and commercialize VEPPANU, the first FDA‑approved PROTAC estrogen receptor degrader for certain advanced or metastatic breast cancers.
Arvinas and Pfizer will receive a $70 million upfront payment and an additional $15 million tied to specified transition activities, shared evenly between them. They may earn up to $320 million in future development, regulatory and commercial milestone payments, plus tiered royalties in the mid‑teens to mid‑20s on worldwide net sales. Rigel will lead U.S. launch and commercialization, hold global rights with sublicensing ability, and contribute up to $40 million toward ongoing development. Closing is subject to customary conditions, including Hart‑Scott‑Rodino antitrust clearance.
Arvinas, Pfizer and Rigel have signed a major licensing deal for VEPPANU. Rigel will receive exclusive global rights to develop, manufacture and commercialize VEPPANU, the first FDA‑approved PROTAC estrogen receptor degrader for certain advanced or metastatic breast cancers.
Arvinas and Pfizer will receive a $70 million upfront payment and an additional $15 million tied to specified transition activities, shared evenly between them. They may earn up to $320 million in future development, regulatory and commercial milestone payments, plus tiered royalties in the mid‑teens to mid‑20s on worldwide net sales. Rigel will lead U.S. launch and commercialization, hold global rights with sublicensing ability, and contribute up to $40 million toward ongoing development. Closing is subject to customary conditions, including Hart‑Scott‑Rodino antitrust clearance.
Arvinas reported a sharp year-over-year swing to a Q1 2026 loss as one-time collaboration revenue from 2025 rolled off, while its first PROTAC drug gained FDA approval shortly after quarter-end. Revenue fell to $15.6 million from $188.8 million, largely because the prior-year period included a major accounting estimate change that accelerated Vepdegestrant collaboration revenue.
Research and development expense declined to $60.3 million from $90.8 million and general and administrative expense dropped to $19.1 million, reflecting restructuring and cost controls. Net loss was $57.6 million, or $0.90 per share, versus net income of $82.9 million a year earlier. Cash, cash equivalents and marketable securities totaled $614.9 million, which management believes can fund operations into the second half of 2028.
Subsequent to quarter-end, the FDA approved VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, the first FDA-approved PROTAC protein degrader, triggering a $50.0 million milestone from Pfizer, partially payable to Yale under a license. Arvinas continues to advance a broad pipeline, including ARV-102 for neurodegenerative diseases, ARV-806 for KRAS G12D-mutant cancers, ARV-393 for non-Hodgkin lymphoma, ARV-027 for Kennedy's disease, and preclinical programs such as ARV-6723 and a pan-KRAS degrader.
Arvinas, Inc. submitted a Form 144 notice relating to proposed sales of Common Stock. The filing lists 11,343 shares tied to the 05/11/2026 settlement of vested restricted stock units through Morgan Stanley Smith Barney LLC. The filing also records a prior sale of 5,134 shares by Andrew Saik on 02/13/2026 for $61,043.26.
Arvinas, Inc. reports a proposed sale of 9,834 shares. The Form 144 lists the sale as settlement of vested restricted stock units to be sold on 05/11/2026. The filing also shows prior dispositions in the past three months of 4,592 and 3,609 shares with dollar proceeds noted.